ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Hydroxychloroquine"

  • Abstract Number: 0875 • ACR Convergence 2021

    Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity

    Shivani Garg1, Karen Hansen2, Betty Chewning1 and Christie Bartels2, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
  • Abstract Number: 0989 • ACR Convergence 2021

    Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users

    April Jorge1, Ronald Melles2, Carol Conell3, Na Lu4, Michael Marmor5, Lucy Young6, Natalie McCormick1, Yuqing Zhang7 and Hyon K. Choi8, 1Massachusetts General Hospital, Boston, MA, 2Redwood City Medical Center, Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, 3Kaiser Permanente Northern California, Palo Alto, CA, 4Arthritis Research Canada, Vancouver, BC, Canada, 5Stanford University, Palo Alto, CA, 6Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA, 7Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 8Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…
  • Abstract Number: 1163 • ACR Convergence 2021

    Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence

    Shivani Garg1, Betty Chewning1, Noah Kaitz1, Shelby Gomez1 and Christie Bartels2, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of SLE therapy as it improves damage-free survival in all SLE patients. Yet, in new users, as few as…
  • Abstract Number: 1462 • ACR Convergence 2021

    Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares

    April Jorge1, Christian Mancini1, Xiaoqing Fu1, Gary Ho2, Yuqing Zhang3, Karen Costenbader4 and Hyon K. Choi5, 1Massachusetts General Hospital, Boston, MA, 2New York University, New York, NY, 3Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital, Belmont, MA, 5Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is an important treatment for systemic lupus erythematosus (SLE), known to reduce disease activity and flares. To minimize the risk of toxicity,…
  • Abstract Number: 1705 • ACR Convergence 2021

    The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users

    Marco Gianpiero Antivalle1, Michele Agosti1, Giuliana La Paglia2, Alberto Batticciotto3, Maria Chiara Ditto4, SIMONE PARISI5 and Piercarlo Sarzi-Puttini6, 1L. Sacco University Hospital, Milano, Italy, 2L.Sacco University Hospital, Milano, Lombardia, Italy, 3Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, 4AOU Città della Salute e della Scienza, Torino, Italy, 5AOU Città della Salute e della Scienza, TURIN, Italy, 6L.Sacco University Hospital, Milano, Italy

    Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…
  • Abstract Number: 1743 • ACR Convergence 2021

    Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity

    Mayce Haj-Ali1 and H. Michael Belmont2, 1NYU Grossman School of Medicine, New York, NY, 2NYU School of Medicine, New York, NY

    Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). There is limited data assessing cardiac toxicity as arrhythmias…
  • Abstract Number: 1753 • ACR Convergence 2021

    Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors

    Laurence Magder1, Michelle Petri2 and Daniel Goldman2, 1University of Maryland, Baltimore, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
  • Abstract Number: 1764 • ACR Convergence 2021

    Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients

    Kelley Brady, Roberta Alexander, Rory Bloch, Mark Rudolph, Karina Baggiani, Deborah Stimson and Anja Kammensheidt, Exagen Inc., Vista, CA

    Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…
  • Abstract Number: 1768 • ACR Convergence 2021

    Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity

    Risa Wakiya1, Kiyo Ueeda1, Hiromi Shimada1, Shusaku Nakashima1, Mikiya Kato1, Taichi Miyagi2, Mansour mai1, Koichi Sugihara1, Rina Semba1, Mao Mizusaki1, Tomohiro Kameda1 and Hiroaki Dobashi3, 1Kagawa University, Takamatsu, Japan, 2Kagawa University, Kidagun, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: In systemic lupus erythematosus (SLE), atherosclerosis is strongly associated with vital prognosis. On the other hand, arteriosclerosis is strongly influenced by serum adipokines. The…
  • Abstract Number: 2560 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

    Maria Salgado Guerrero1, Alejandra Londono Jimenez 2, Chrisanna Dobrowolsky 2, Shudan Wang 2, Wenzhu B. Mowrey 3 and Anna Broder 2, 1Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Hydroxychloroquine (HCQ) use in SLE has been associated with a lower risk of end-organ damage, SLE flares, and thrombosis1,2. However the benefits of HCQ…
  • Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting

    Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

    Tatiana Pedrosa 1, Sandra G. Pasoto 1, Emily Yuki2, Nadia Aikawa 1, Eduardo Borba 1, Julio Ferreira Filho 1, Pedro Carricondo 3, Caio Zanetti 1, Paola Conde 1, Nicole Fontoura 1, Paschoalina Romano 4, Valdemir Carvalho 5, Clovis Silva 6 and Eloisa Bonfa 7, 1Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, 3Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 4Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 5Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, 6Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
  • Abstract Number: 320 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

    Rebecca Overbury1, Jakrapun Pupaibool 2, Christopher Hansen 3, Daniel Clegg 4 and Dorota Lebiedz-Odrobina 5, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2University of Utah, Division of Infectious Diseases, Salt Lake City, UT, 3University of Utah, Department of Dermatology, Salt Lake City, UT, 4University of Utah, Salt Lake City, UT, 5University of Utah, Division of Rheumatology, Salt Lake City, UT

    Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
  • Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting

    Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

    Gemma Cramarossa1, Janet Pope 2 and Matthew Turk 3, 1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, 2Western University, London, ON, Canada, 3University of Western Ontario, London, ON, Canada

    Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
  • Abstract Number: 321 • 2019 ACR/ARP Annual Meeting

    Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus

    Tara Skorupa1 and Robert Shmerling 1, 1Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
  • Abstract Number: 2573 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels

    Benoit Blanchet 1, Jallouli Moez 2, Marie Allard 3, veronique le guern 4, Jean-Charles Piette 5, Noémie Jourde-Chiche 6 and Nathalie Costedoat-Chalumeau7, 1Cochin, Paris, France, 2sfax, SFAX, Tunisia, 3Hôpital Bichat Claude-Bernard, Paris, France, 4APHP, paris, France, 5Hôpital Pitié-Salpêtrière, Paris, France, 6APHM, Marseille, Marseille, France, 7Cochin University Hospital, Paris, France

    Background/Purpose: Hydroxychloroquine (HCQ) levels can be measured in whole blood as well as in serum but both methods have never been compared. Cut offs for…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences